Depressive Disorder, Major

• 

  Subject Areas on Research

  • A Brief Clinical Tool to Estimate Individual Patients' Risk of Depressive Relapse Following Remission: Proof of Concept. 
  • A Comparison of the QIDS-C16, QIDS-SR16, and the MADRS in an Adult Outpatient Clinical Sample. 
  • A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. 
  • A New Empirical Definition of Major Depressive Episode Recovery and Its Positive Impact on Future Course of Illness. 
  • A Novel Strategy to Identify Placebo Responders: Prediction Index of Clinical and Biological Markers in the EMBARC Trial. 
  • A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. 
  • A Step Toward Optimizing Treatment Schedules for Continuation ECT: Response to Rasmussen. 
  • A Structured Approach to Detecting and Treating Depression in Primary Care: VitalSign6 Project. 
  • A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction. 
  • A case of transient hallucination with ropinirole augmentation antidepressant in a patient with treatment-resistant depression: Is there differential effect of ropinirole dose on developing psychotic symptom? 
  • A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial. 
  • A comparison of alternative assessments of depressive symptom severity: a pilot study. 
  • A comparison of alternative assessments of depressive symptom severity: a pilot study. 
  • A comparison of baseline sociodemographic and clinical characteristics between major depressive disorder patients with and without diabetes: a STAR*D report. 
  • A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression. 
  • A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. 
  • A comparison of pure and comorbid CD/ODD and depression. 
  • A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. 
  • A conceptual introduction to cognitive remediation for memory deficits associated with right unilateral electroconvulsive therapy. 
  • A descriptive analysis of minor depression. 
  • A direct comparison of presenting characteristics of depressed outpatients from primary vs. specialty care settings: preliminary findings from the STAR*D clinical trial. 
  • A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). 
  • A double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depression. 
  • A family study of chronic post-traumatic stress disorder following rape trauma. 
  • A fidelity measure for integrated management of depression in primary care. 
  • A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. 
  • A longitudinal examination of the psychoeducational, neurocognitive, and psychiatric functioning in children with 22q11.2 deletion syndrome. 
  • A longitudinal study of differences in late- and early-onset geriatric depression: depressive symptoms and psychosocial, cognitive, and neurological functioning. 
  • A manual-based intervention to address clinical crises and retain patients in the Treatment of Adolescents With Depression Study (TADS). 
  • A multi-site randomized clinical trial to reduce suicidal ideation in suicidal adult outpatients with Major Depressive Disorder: Development of a methodology to enhance safety. 
  • A practical approach to the early identification of antidepressant medication non-responders. 
  • A psychometric evaluation of the CDRS and MADRS in assessing depressive symptoms in children. 
  • A psychometric evaluation of the clinician-rated Quick Inventory of Depressive Symptomatology (QIDS-C16) in patients with bipolar disorder. 
  • A randomized trial of citalopram versus placebo in outpatients with asthma and major depressive disorder: a proof of concept study. 
  • A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. 
  • A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. 
  • A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies. 
  • A systematic review of relations between resting-state functional-MRI and treatment response in major depressive disorder. 
  • A systematic review of the association between biological markers and environmental stress risk factors for adolescent depression. 
  • A systematic review of treatments for refractory depression in older people. 
  • AGTR1 gene variation: association with depression and frontotemporal morphology. 
  • APOE genotype and hippocampal volume change in geriatric depression. 
  • Acceptability of second-step treatments to depressed outpatients: a STAR*D report. 
  • Acetyl-l-carnitine deficiency in patients with major depressive disorder. 
  • Achievement and maintenance of sustained response during the Treatment for Adolescents With Depression Study continuation and maintenance therapy. 
  • Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. 
  • Acupuncture: a promising treatment for depression during pregnancy. 
  • Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. 
  • Acute time to response in the Treatment for Adolescents with Depression Study (TADS). 
  • Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes. 
  • Adequacy of antidepressant treatment by psychiatric residents: the antidepressant treatment history form as a possible assessment tool. 
  • Adherence to antidepressant combinations and monotherapy for major depressive disorder: a CO-MED report of measurement-based care. 
  • Adjunctive brexpiprazole for the treatment of major depressive disorder. 
  • Adjunctive use of olanzapine in mood disorders: five case reports. 
  • Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults. 
  • Adverse childhood experiences and depression among women in rural Pakistan. 
  • Affective context interferes with cognitive control in unipolar depression: an fMRI investigation. 
  • Age differences in symptom expression in patients with major depression. 
  • Age-related characteristics of depression: a preliminary STAR*D report. 
  • Aggression after traumatic brain injury: prevalence and correlates. 
  • Algorithms For Treatment of Major Depressive Disorder: Efficacy and Cost-Effectiveness. 
  • Allelic differences in the brain-derived neurotrophic factor Val66Met polymorphism in late-life depression. 
  • Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression. 
  • Altered striatal activation predicting real-world positive affect in adolescent major depressive disorder. 
  • Amygdala volume in late-life depression: relationship with age of onset. 
  • Amyloid-associated depression: a prodromal depression of Alzheimer disease? 
  • An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. 
  • An Electrophysiological Biomarker That May Predict Treatment Response to ECT. 
  • An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials. 
  • An ecological-transactional model of significant risk factors for child psychopathology in outer mongolia. 
  • An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. 
  • An exploration of comorbid depression among female victims of intimate partner violence with posttraumatic stress disorder. 
  • An exploratory analysis of the impact of family functioning on treatment for depression in adolescents. 
  • An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder. 
  • An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial). Sertraline Anti-Depressant Heart Attack Trial. 
  • Anger, social support, and suicide risk in U.S. military veterans. 
  • Anticipated Benefits of Care (ABC): psychometrics and predictive value in psychiatric disorders. 
  • Antidepressant Regulatory Warnings, Prescription Patterns, Suicidality and Other Aggressive Behaviors in Major Depressive Disorder and Anxiety Disorders. 
  • Antidepressant response to electroconvulsive therapy is sustained after catecholamine depletion. 
  • Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report. 
  • Anxiety reduces baroreflex cardiac control in older adults with major depression. 
  • Appetite and Weight Loss Symptoms in Late-Life Depression Predict Dementia Outcomes. 
  • Appetite loss and neurocognitive deficits in late-life depression. 
  • Applications of TMS to therapy in psychiatry. 
  • Are Patients with Childhood Onset of Insomnia and Depression More Difficult to Treat Than Are Those with Adult Onsets of These Disorders? A Report from the TRIAD Study. 
  • Are depressed outpatients with and without a family history of substance use disorder different? A baseline analysis of the STAR*D cohort. 
  • As fathers and felons: explaining the effects of current and recent incarceration on major depression. 
  • Ascending digits task as a measure of executive function in geriatric depression. 
  • Assessing patient beliefs in a clinical trial of Hypericum perforatum in major depression. 
  • Assessing the preventive effects of cognitive therapy following relief of depression: A methodological innovation. 
  • Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute working group report. 
  • Assessment of safety and long-term outcomes of initial treatment with placebo in TADS. 
  • Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. 
  • Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. 
  • Association between major depressive episodes in patients with chronic kidney disease and initiation of dialysis, hospitalization, or death. 
  • Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. 
  • Association of AGTR1 with 18-month treatment outcome in late-life depression. 
  • Association of DHEA, DHEAS, and cortisol with childhood trauma exposure and post-traumatic stress disorder. 
  • Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. 
  • Association of attentional shift and reversal learning to functional deficits in geriatric depression. 
  • Association of five-factor model personality domains and facets with presence, onset, and treatment outcomes of major depression in older adults. 
  • Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs. 
  • Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. 
  • Association of somatic symptoms with depression and anxiety in clinical patients of general hospitals in Guangzhou, China. 
  • Associations between sleep difficulties and risk factors for cardiovascular disease in veterans and active duty military personnel of the Iraq and Afghanistan conflicts. 
  • Attenuation of Frontostriatal Connectivity During Reward Processing Predicts Response to Psychotherapy in Major Depressive Disorder. 
  • Atypical depression: a comprehensive review. 
  • BDNF Val66Met genotype and 6-month remission rates in late-life depression. 
  • Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. 
  • Baroreceptor sensitivity at rest and during stress in women with posttraumatic stress disorder or major depressive disorder. 
  • Basolateral amygdala volume and cell numbers in major depressive disorder: a postmortem stereological study. 
  • Behavioral and emotional disturbances in the offspring of depressed parents with anger attacks. 
  • Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics. 
  • Better, Faster, Safer: Exploring Biomarkers of Response to Transform Electroconvulsive Therapy. 
  • Biochemical abnormalities of the medial temporal lobe and medial prefrontal cortex in late-life depression. 
  • Bioequivalence and Therapeutic Equivalence of Generic and Brand Bupropion in Adults With Major Depression: A Randomized Clinical Trial. 
  • Biological and social predictors of long-term geriatric depression outcome. 
  • Bipolar disorder is associated with HIV transmission risk behavior among patients in treatment for HIV. 
  • Blinding and bias in a hypnotic clinical trial. 
  • Brain network functional connectivity and cognitive performance in major depressive disorder. 
  • Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment. 
  • Brief pulse and ultrabrief pulse right unilateral electroconvulsive therapy (ECT) for major depression: efficacy, effectiveness, and cognitive effects. 
  • Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the research domain criteria (RDoC). 
  • Bupropion in the treatment of outpatients with asthma and major depressive disorder. 
  • Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. 
  • Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. 
  • Can psychological features predict antidepressant response to rTMS? A Discovery-Replication approach. 
  • Cardiovascular disease risk, vascular health and erectile dysfunction among middle-aged, clinically depressed men. 
  • Case report of treatment of severe mood disorder in an inpatient setting: when less is more. 
  • Cerebrospinal fluid metabolome in mood disorders-remission state has a unique metabolic profile. 
  • Cerebrovascular risk factors and cerebral hyperintensities among middle-aged and older adults with major depression. 
  • Cerebrovascular risk factors, vascular disease, and neuropsychological outcomes in adults with major depression. 
  • Challenging assumptions from emotion dysregulation psychological treatments. 
  • Changes in depressive symptoms and social functioning in the sequenced treatment alternatives to relieve depression study. 
  • Childhood exposure to ambient air pollution and predicting individual risk of depression onset in UK adolescents. 
  • Childhood maltreatment and impact on clinical features of major depression in adults. 
  • Childhood traumatic stress and obesity in women: the intervening effects of PTSD and MDD. 
  • Children of currently depressed mothers: a STAR*D ancillary study. 
  • Children of depressed mothers 1 year after remission of maternal depression: findings from the STAR*D-Child study. 
  • Children of depressed mothers 1 year after the initiation of maternal treatment: findings from the STAR*D-Child Study. 
  • Chronic Vagus Nerve Stimulation Significantly Improves Quality of Life in Treatment-Resistant Major Depression. 
  • Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. 
  • Chronobiologic parameter changes in patients with major depressive disorder and sleep disturbance treated with adjunctive brexpiprazole: An open-label, flexible-dose, exploratory substudy. 
  • Church attendance and new episodes of major depression in a community study of older adults: the Cache County Study. 
  • Cingulum bundle white matter lesions influence antidepressant response in late-life depression: a pilot study. 
  • Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression. 
  • Clinical and demographic factors associated with DSM-IV melancholic depression. 
  • Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. 
  • Clinical and sociodemographic characteristics associated with suicidal ideation in depressed outpatients. 
  • Clinical and sociodemographic correlates of suicidality in patients with major depressive disorder from six Asian countries. 
  • Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. 
  • Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study. 
  • Clinical differences among depressed patients with and without a history of suicide attempts: findings from the STAR*D trial. 
  • Clinical features of depressed outpatients with and without co-occurring general medical conditions in STAR*D. 
  • Clinical features of depression in Asia: results of a large prospective, cross-sectional study. 
  • Clinical features of patients with treatment-emergent suicidal behavior following initiation of paroxetine therapy. 
  • Clinical research challenges posed by difficult-to-treat depression. 
  • Clinical vs. self-report versions of the quick inventory of depressive symptomatology in a public sector sample. 
  • Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression. 
  • Clomipramine and glucocorticoid receptor function. 
  • Closed-loop neuromodulation in an individual with treatment-resistant depression. 
  • Coexistence of urinary incontinence and major depressive disorder with health-related quality of life in older Americans with and without cancer. 
  • Cognitive Behavioral Insomnia Therapy for Those With Insomnia and Depression: A Randomized Controlled Clinical Trial. 
  • Cognitive aspects of chronic depression. 
  • Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial. 
  • Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. 
  • Cognitive functioning throughout the treatment history of clinical late-life depression. 
  • Cognitive measures of adolescent depression: unique or unitary constructs? 
  • Cognitive performance in antidepressant-free recurrent major depressive disorder. 
  • Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. 
  • Cognitive variability, brain aging, and cognitive decline in late-life major depression. 
  • Cognitive-behavioral analysis system of psychotherapy as a maintenance treatment for chronic depression. 
  • Cognitive-behavioral therapy for suicide prevention (CBT-SP): treatment model, feasibility, and acceptability. 
  • Combined catecholamine and indoleamine depletion following response to ECT. 
  • Combining antidepressant medications: a good idea? 
  • Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. 
  • Comment on Nasrallah et al: lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol. 
  • Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. 
  • Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder. 
  • Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. 
  • Comorbidity and depression treatment. 
  • Comparative efficacy of cognitive behavioral therapy, fluoxetine, and their combination in depressed adolescents: initial lessons from the treatment for adolescents with depression study. 
  • Comparison of academic and nonacademic sites in multi-center clinical trials. 
  • Comparison of brain structural variables, neuropsychological factors, and treatment outcome in early-onset versus late-onset late-life depression. 
  • Comparison of major and minor depression in older medical inpatients with chronic heart and pulmonary disease. 
  • Comparison of older depressed hospitalized patients with and without heart failure/pulmonary disease. 
  • Comparison of post-disaster psychiatric disorders after terrorist bombings in Nairobi and Oklahoma City. 
  • Comparison of quality of life measures in a depressed population. 
  • Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT. 
  • Comparison of self-report and clinician ratings on two inventories of depressive symptomatology. 
  • Computerized cognitive training and functional recovery in major depressive disorder: A meta-analysis. 
  • Concerns about data reporting and interpretation in "Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial". 
  • Concise Associated Symptoms Tracking scale: a brief self-report and clinician rating of symptoms associated with suicidality. 
  • Concise Health Risk Tracking scale: a brief self-report and clinician rating of suicidal risk. 
  • Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. 
  • Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression. 
  • Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. 
  • Correlates and outcomes of depressed out-patients with greater and fewer anxious symptoms: a CO-MED report. 
  • Cortical thickness predicts remission of depression with antidepressants in patients with late-life depression and cognitive impairment. 
  • Cortisol and development of depression in adolescence and young adulthood - a systematic review and meta-analysis. 
  • Cost-effectiveness of improving primary care treatment of late-life depression. 
  • Cost-effectiveness of treatments for adolescent depression: results from TADS. 
  • Cross-cultural considerations in administering the center for epidemiologic studies depression scale. 
  • Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. 
  • Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. 
  • DHEA metabolism to the neurosteroid androsterone: a possible mechanism of DHEA's antidepressant action. 
  • Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. 
  • Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. 
  • Decreased Resting-State Activity in the Precuneus Is Associated With Depressive Episodes in Recurrent Depression. 
  • Default mode network connectivity in children with a history of preschool onset depression. 
  • Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines. 
  • Depressed adolescents and comorbid psychiatric disorders: are there differences in the presentation of depression? 
  • Depressed older patients with the atypical features of interpersonal rejection sensitivity and reversed-vegetative symptoms are similar to younger atypical patients. 
  • Depression Among Older Adults: A 20-Year Update on Five Common Myths and Misconceptions. 
  • Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial. 
  • Depression after successful treatment for nonsmall cell lung carcinoma. 
  • Depression among military spouses: Demographic, military, and service member psychological health risk factors. 
  • Depression and Bipolar Support Alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in late life. 
  • Depression and five year survival following acute myocardial infarction: a prospective study. 
  • Depression and generalized anxiety disorder: cumulative and sequential comorbidity in a birth cohort followed prospectively to age 32 years. 
  • Depression in Taiwanese patients with Alzheimer's disease determined by the National Institutes of Mental Health Provisional Criteria. 
  • Depression in chronic illness: does religion help? 
  • Depression in patients with colorectal cancer in Saudi Arabia. 
  • Depression outcome in inpatients with congestive heart failure. 
  • Depression outcomes of Spanish- and english-speaking Hispanic outpatients in STAR*D. 
  • Depression treatment in patients with general medical conditions: results from the CO-MED trial. 
  • Depression, suicidality, and alcohol use disorder among people living with HIV/AIDS in Nigeria. 
  • Depressive morbidity and gender in community-dwelling Brazilian elderly: systematic review and meta-analysis. 
  • Depressive state- and disease-related alterations in neural responses to affective and executive challenges in geriatric depression. 
  • Depressive symptoms and clinical status during the Treatment of Adolescent Suicide Attempters (TASA) Study. 
  • Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. 
  • Detection of depression in low resource settings: validation of the Patient Health Questionnaire (PHQ-9) and cultural concepts of distress in Nepal. 
  • Development of a semi-automated method for quantification of MRI gray and white matter lesions in geriatric subjects. 
  • Diagnostic specificity and nonspecificity in the dimensions of preschool psychopathology. 
  • Diagnostic utility of the Quick Inventory of Depressive Symptomatology (QIDS-C16 and QIDS-SR16) in the elderly. 
  • Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. 
  • Differences between depressed patients with heart failure and those with pulmonary disease. 
  • Differences between suicide attempters and nonattempters in depressed older patients: depression severity, white-matter lesions, and cognitive functioning. 
  • Differences in behavioral health disorders and unmet treatment needs between medical marijuana users and recreational marijuana users: Results from a national adult sample. 
  • Differences in early childhood risk factors for juvenile-onset and adult-onset depression. 
  • Differential response to SSRI versus Placebo and distinct neural signatures among data-driven subgroups of patients with major depressive disorder. 
  • Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. 
  • Digital Intervention for Cognitive Deficits in Major Depression: A Randomized Controlled Trial to Assess Efficacy and Safety in Adults. 
  • Dimensions of social support and depression in patients at increased psychosocial risk recovering from myocardial infarction. 
  • Direct Participation in and Indirect Exposure to the Occupy Central Movement and Depressive Symptoms: A Longitudinal Study of Hong Kong Adults. 
  • Disability but not social support predicts cognitive deterioration in late-life depression. 
  • Discussing Out-of-Pocket Expenses During Clinical Appointments: An Observational Study of Patient-Psychiatrist Interactions. 
  • Disrupted amygdala reactivity in depressed 4- to 6-year-old children. 
  • Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors. 
  • Distinguishing functional from syndromal recovery: implications for clinical care and research. 
  • Diurnal mood variation in outpatients with major depressive disorder. 
  • Diurnal mood variation in outpatients with major depressive disorder: implications for DSM-V from an analysis of the Sequenced Treatment Alternatives to Relieve Depression Study data. 
  • Divergent Outcomes in Cognitive-Behavioral Therapy and Pharmacotherapy for Adult Depression. 
  • Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial. 
  • Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? 
  • Do estradiol levels influence on the cognitive function during antidepressant treatments in post-menopausal women with major depressive disorder? A comparison with pre-menopausal women. 
  • Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. 
  • Does Childhood Trauma Moderate Polygenic Risk for Depression? A Meta-analysis of 5765 Subjects From the Psychiatric Genomics Consortium. 
  • Does a coexisting anxiety disorder predict persistence of depressive illness in primary care patients with major depression? 
  • Does change in ECT electrode placement help temporomandibular joint pain? 
  • Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. 
  • Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report. 
  • Does pretreatment insomnia or anxiety predict acute response to bupropion SR? 
  • Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. 
  • Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report. 
  • Dropouts versus completers among chronically depressed outpatients. 
  • Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. 
  • Dyadic discord at baseline is associated with lack of remission in the acute treatment of chronic depression. 
  • Dynamic Resting-State Functional Connectivity in Major Depression. 
  • Dynamically Timed Stimulation of Corticolimbic Circuitry Activates a Stress-Compensatory Pathway. 
  • Dysfunctional attitudes scale perfectionism: a predictor and partial mediator of acute treatment outcome among clinically depressed adolescents. 
  • Dysregulation of Prefrontal Cortex-Mediated Slow-Evolving Limbic Dynamics Drives Stress-Induced Emotional Pathology. 
  • ECT and TMS: past, present, and future. 
  • ECT use in unipolar and bipolar depression. 
  • EEG biomarker informed prescription of antidepressants in MDD: a feasibility trial. 
  • EEG effects of ECT: implications for rTMS. 
  • EFFECTS OF RELIGIOUS VERSUS STANDARD COGNITIVE-BEHAVIORAL THERAPY ON OPTIMISM IN PERSONS WITH MAJOR DEPRESSION AND CHRONIC MEDICAL ILLNESS. 
  • ERICH3: vesicular association and antidepressant treatment response. 
  • Early Improvement in Work Productivity Predicts Future Clinical Course in Depressed Outpatients: Findings From the CO-MED Trial. 
  • Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report. 
  • Easing the burden of social anxiety disorder. 
  • Effect and neural mechanisms of the transcutaneous vagus nerve stimulation for relapse prevention in patients with remitted major depressive disorder: protocol for a longitudinal study. 
  • Effect of Extended Release Bupropion on Unilateral Ultrabrief Electroconvulsive Therapy Seizure Parameters in Major Depressive Disorder. 
  • Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. 
  • Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. 
  • Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial. 
  • Effect of age at onset on the course of major depressive disorder. 
  • Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study. 
  • Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression. 
  • Effect of bupropion extended release on negative emotion processing in major depressive disorder: a pilot functional magnetic resonance imaging study. 
  • Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial. 
  • Effect of mirtazapine orally disintegrating tablets on health-related quality of life in elderly depressed patients with comorbid medical disorders: a pilot study. 
  • Effect of the Patient-Centered Medical Home on Racial Disparities in Quality of Care. 
  • Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: a pilot study on differential effects of sex hormones on antidepressant effects. 
  • Effects of Adjunctive Brexpiprazole on Sleep Disturbances in Patients With Major Depressive Disorder: An Open-Label, Flexible-Dose, Exploratory Study. 
  • Effects of Exercise and Sertraline on Measures of Coronary Heart Disease Risk in Patients With Major Depression: Results From the SMILE-II Randomized Clinical Trial. 
  • Effects of a Course of Right Unilateral Ultrabrief Pulse Electroconvulsive Therapy Combined With Venlafaxine on Insomnia Symptoms in Elderly Depressed Patients. 
  • Effects of continuation electroconvulsive therapy on quality of life in elderly depressed patients: A randomized clinical trial. 
  • Effects of early life stress on depression, cognitive performance and brain morphology. 
  • Effects of heart disease on depression treatment: results from the COMED study. 
  • Effects of pulse width and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. 
  • Effects of race and ethnicity on depression treatment outcomes: the CO-MED trial. 
  • Effects of religious vs. standard cognitive behavioral therapy on therapeutic alliance: A randomized clinical trial. 
  • Effects on Daily Spiritual Experiences of Religious Versus Conventional Cognitive Behavioral Therapy for Depression. 
  • Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression. 
  • Efficacy and acceptability of transcranial direct current stimulation (tDCS) for major depressive disorder: An individual patient data meta-analysis. 
  • Efficacy and safety of St. John's wort for the treatment of major depression. 
  • Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis. 
  • Efficacy of Cognitive-Behavioral Therapy for Insomnia Combined With Antidepressant Pharmacotherapy in Patients With Comorbid Depression and Insomnia: A Randomized Controlled Trial. 
  • Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. 
  • Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies. 
  • Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. 
  • Electric field characteristics of low-field synchronized transcranial magnetic stimulation (sTMS). 
  • ElectroConvulsive therapy Cognitive Assessment (ECCA) tool: A new instrument to monitor cognitive function in patients undergoing ECT. 
  • Electroconvulsive Therapy Pulse Amplitude and Clinical Outcomes. 
  • Electroconvulsive Therapy and All-Cause Mortality in Texas, 1998-2013. 
  • Electroconvulsive therapy (ECT) for moderate-severity major depression among the elderly: Data from the pride study. 
  • Electroconvulsive therapy device classification: response to FDA advisory panel hearing and recommendations. 
  • Electroconvulsive therapy for depression. 
  • Electroconvulsive therapy for severe major depressive disorder after orthotopic liver transplantation. 
  • Electroconvulsive therapy in the United States: how often is it used? 
  • Electroconvulsive therapy: how effective is it? 
  • Electronic source materials in clinical research: acceptability and validity of symptom self-rating in major depressive disorder. 
  • Elevated brain lesion volumes in older adults who use calcium supplements: a cross-sectional clinical observational study. 
  • Elevated inflammation levels in depressed adults with a history of childhood maltreatment. 
  • Elevation in plasma Abeta42 in geriatric depression: a pilot study. 
  • Emotion Regulation in Borderline Personality Disorder: An Experimental Investigation of the Effects of Instructed Acceptance and Suppression. 
  • Empirically derived subtypes of adolescent depression: latent profile analysis of co-occurring symptoms in the Treatment for Adolescents with Depression Study (TADS). 
  • Enrolling research subjects from clinical practice: ethical and procedural issues in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. 
  • Equivalency of the diagnostic accuracy of the PHQ-8 and PHQ-9: a systematic review and individual participant data meta-analysis. 
  • Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. 
  • Estimating optimal shared-parameter dynamic regimens with application to a multistage depression clinical trial. 
  • Ethnic differences among adolescents beginning treatment for depression. 
  • Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. 
  • Evaluation of lifetime trauma exposure and physical health in women with posttraumatic stress disorder or major depressive disorder. 
  • Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. 
  • Evidence for impaired cortical inhibition in patients with unipolar major depression. 
  • Evidence for increased glutamatergic cortical facilitation in children and adolescents with major depressive disorder. 
  • Evidence of causal effect of major depression on alcohol dependence: findings from the psychiatric genomics consortium. 
  • Evidence of early retinal microvascular changes in patients with type 2 diabetes and depression. 
  • Examining suicide assessment measures for research use: Using item response theory to optimize psychometric assessment for research on suicidal ideation in major depressive disorder. 
  • Examining the factor structure of the Connor-Davidson Resilience Scale (CD-RISC) in a post-9/11 U.S. military veteran sample. 
  • Exercise and pharmacotherapy in patients with major depression: one-year follow-up of the SMILE study. 
  • Exercise and pharmacotherapy in the treatment of major depressive disorder. 
  • Exercise fails to improve neurocognition in depressed middle-aged and older adults. 
  • Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. 
  • Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. 
  • External validation of a shortened screening tool using individual participant data meta-analysis: A case study of the Patient Health Questionnaire-Dep-4. 
  • Factor structure and dimensionality of the two depression scales in STAR*D using level 1 datasets. 
  • Factor structure and psychometric properties of the Children's Negative Cognitive Error Questionnaire with a clinically depressed adolescent sample. 
  • Factors associated with chronic depressive episodes: a preliminary report from the STAR-D project. 
  • Factors associated with concomitant psychotropic drug use in the treatment of major depression: a STAR*D Report. 
  • Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. 
  • Factors that differentiate early vs. later onset of major depression disorder. 
  • Family history of completed suicide and characteristics of major depressive disorder: a STAR*D (sequenced treatment alternatives to relieve depression) study. 
  • Family history of depression and therapeutic outcome: findings from STAR*D. 
  • Family history of mood disorder and characteristics of major depressive disorder: a STAR*D (sequenced treatment alternatives to relieve depression) study. 
  • Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone. 
  • Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion. 
  • Fiber tract-specific white matter lesion severity Findings in late-life depression and by AGTR1 A1166C genotype. 
  • Financial well-being and postdeployment adjustment among Iraq and Afghanistan war veterans. 
  • Five-year trajectories of social networks and social support in older adults with major depression. 
  • Flexible dosing schedules for continuation electroconvulsive therapy. 
  • Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. 
  • Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. 
  • Focal and lateralized subcortical abnormalities in unipolar major depressive disorder: an automated multivoxel proton magnetic resonance spectroscopy study. 
  • Focal brain stimulation with repetitive transcranial magnetic stimulation (rTMS): implications for the neural circuitry of depression. 
  • Folate and unipolar depression. 
  • Follow-up visits by provider specialty for patients with major depressive disorder initiating antidepressant treatment. 
  • Food group intake and brain lesions in late-life vascular depression. 
  • Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies. 
  • Functional brain activation to emotionally valenced faces in school-aged children with a history of preschool-onset major depression. 
  • Functional connectivity of the amygdala in early-childhood-onset depression. 
  • Functional connectivity predictors of acute depression treatment outcome. 
  • Functional connectivity: a source of variance in the association between cardiorespiratory fitness and cognition? 
  • Functioning and interpersonal relationships as predictors of response in treatment-resistant depression. 
  • Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS). 
  • Gender differences in depression: findings from the STAR*D study. 
  • Gender differences in the association between religious involvement and depression: the Cache County (Utah) study. 
  • Gender-specific structural abnormalities in major depressive disorder revealed by fixel-based analysis. 
  • General medical and specialty mental health service use for major depression. 
  • Generalized anxiety disorder and depression: childhood risk factors in a birth cohort followed to age 32. 
  • Genetic Association of Major Depression With Atypical Features and Obesity-Related Immunometabolic Dysregulations. 
  • Genetic association study of individual symptoms in depression. 
  • Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. 
  • Genetic prediction of antidepressant drug response and nonresponse in Korean patients. 
  • Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. 
  • Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB. 
  • Genome-Wide Association Study Meta-Analysis of the Alcohol Use Disorders Identification Test (AUDIT) in Two Population-Based Cohorts. 
  • Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. 
  • Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. 
  • Genome-wide interaction study of a proxy for stress-sensitivity and its prediction of major depressive disorder. 
  • Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study. 
  • Geriatric depression and cognitive impairment. 
  • Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. 
  • Greater MRI lesion volumes in elderly depressed subjects than in control subjects. 
  • Grey-matter lesions and dementia. 
  • Guideline-concordant antidepressant use among patients with major depressive disorder. 
  • Hazardous drinking and clinical correlates among suicidal patients receiving psychiatric inpatient care at military medical settings. 
  • Head injury in early adulthood and the lifetime risk of depression. 
  • Heterogeneity in symptom profiles among older adults diagnosed with major depression. 
  • Heterogeneity in the three-year course of major depression among older adults. 
  • Hippocampal volume as a predictor of short-term ECT outcomes in older patients with depression. 
  • Hippocampal volume in geriatric depression. 
  • Hippocampal volume is associated with physician-reported acute cognitive deficits after electroconvulsive therapy. 
  • Hippocampus atrophy and the longitudinal course of late-life depression. 
  • History of depression and survival after acute myocardial infarction. 
  • Hormone therapy does not affect depression severity in older women. 
  • Hyperactivity of the hypothalamic-pituitary-adrenal axis and mortality in major depressive disorder. 
  • Hyperforin plasma level as a marker of treatment adherence in the National Institutes of Health Hypericum Depression Trial. 
  • Identifying depression in primary care: a literature synthesis of case-finding instruments. 
  • Identifying risk for attrition during treatment for depression. 
  • Impact of childhood maltreatment on outcomes of antidepressant medication in chronic and/or recurrent depression. 
  • Impact of childhood trauma on treatment outcome in the Treatment for Adolescents with Depression Study (TADS). 
  • Impact of comorbid panic and posttraumatic stress disorder on outcomes of collaborative care for late-life depression in primary care. 
  • Impact of depression and anxiety on the quality of life of constipated patients. 
  • Impact of diagnosis and treatment of clinically localized prostate cancer on health-related quality of life for older Americans: a population-based study. 
  • Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. 
  • Impact of sleep complaints and depression outcomes among participants in the standard medical intervention and long-term exercise study of exercise and pharmacotherapy for depression. 
  • Impact of symptoms of generalized anxiety disorder on the course of late-life depression. 
  • Impairment and distress patterns distinguishing the melancholic depression subtype: an iSPOT-D report. 
  • Improvement in quality of life with left prefrontal transcranial magnetic stimulation in patients with pharmacoresistant major depression: acute and six month outcomes. 
  • Improvements in Depression and Changes in Fatigue: Results from the SLAM DUNC Depression Treatment Trial. 
  • Improving depression outcomes in older adults with comorbid medical illness. 
  • Improving the chance of recovery from the short- and long-term consequences of depression. 
  • Income and attrition in the treatment of depression: a STAR*D report. 
  • Increased cortical excitability with prefrontal high-frequency repetitive transcranial magnetic stimulation in adolescents with treatment-resistant major depressive disorder. 
  • Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression. 
  • Increased plasma complement factor H is associated with geriatric depression. 
  • Increased prevalence of falls among elderly individuals with mental health and substance abuse conditions. 
  • Increased ventromedial prefrontal cortex activity and connectivity predict poor sertraline treatment outcome in late-life depression. 
  • Increasing the validity of experimental models for depression. 
  • Indicators of pretreatment suicidal ideation in adults with major depressive disorder. 
  • Inflammation Markers and Major Depressive Disorder in Patients With Chronic Heart Failure: Results From the Sertraline Against Depression and Heart Disease in Chronic Heart Failure Study. 
  • Influence of serotonin transporter promoter region polymorphisms on hippocampal volumes in late-life depression. 
  • Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression. 
  • Insight in first-episode psychosis. 
  • Instrumental variable estimation of causal odds ratios using structural nested mean models. 
  • Insured and non-insured depressed outpatients: how do they compare? 
  • Interaction of oxytocin level and past depression may predict postpartum depressive symptom severity. 
  • Interactive effect of substance abuse and depression on adolescent social competence. 
  • International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. 
  • International consensus statement on major depressive disorder. 
  • International randomized-controlled trial of transcranial Direct Current Stimulation in depression. 
  • Intima-media thickness and age of first depressive episode. 
  • Intravenous Ketamine Relieves Pain and Depression After Traumatic Suicide Attempts: A Case Series. 
  • Irritability is associated with anxiety and greater severity, but not bipolar spectrum features, in major depressive disorder. 
  • Is Major Depression Linked to Alcohol-Impaired Driving? 
  • Is depression associated with immune activation? 
  • Is depression associated with microvascular disease in patients with type 2 diabetes? 
  • Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report. 
  • Is there protective haplotype of dysbindin gene (DTNBP1) 3 polymorphisms for major depressive disorder. 
  • Isn't It About Time to Employ Measurement-Based Care in Practice? 
  • Joint analysis of psychiatric disorders increases accuracy of risk prediction for schizophrenia, bipolar disorder, and major depressive disorder. 
  • Ketamine for treatment-resistant depression: ready or not for clinical use? 
  • Key updates in the clinical application of electroconvulsive therapy. 
  • L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. 
  • Largest GWAS of PTSD (N=20 070) yields genetic overlap with schizophrenia and sex differences in heritability. 
  • Late-life Depression Modifies the Association Between Cerebral White Matter Hyperintensities and Functional Decline Among Older Adults. 
  • Late-life depression and microstructural abnormalities in dorsolateral prefrontal cortex white matter. 
  • Left dorsolateral prefrontal transcranial magnetic stimulation (TMS): sleep factor changes during treatment in patients with pharmacoresistant major depressive disorder. 
  • Length of axons expressing the serotonin transporter in orbitofrontal cortex is lower with age in depression. 
  • Lessons from SADHART, ENRICHD, and other trials. 
  • Life Span Studies of ADHD-Conceptual Challenges and Predictors of Persistence and Outcome. 
  • Lifetime major depression and comorbid disorders among current-era women veterans. 
  • Limitations in efficacy of antidepressant monotherapy. 
  • Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. 
  • Localization of age-associated white matter hyperintensities in late-life depression. 
  • Long-Chain Omega-3 Fatty Acid Supplements in Depressed Heart Failure Patients: Results of the OCEAN Trial. 
  • Longitudinal Neurocognitive Effects of Combined Electroconvulsive Therapy (ECT) and Pharmacotherapy in Major Depressive Disorder in Older Adults: Phase 2 of the PRIDE Study. 
  • Longitudinal associations between adolescents' individualised risk for depression and inflammation in a UK cohort study. 
  • Longitudinal magnetic resonance imaging vascular changes, apolipoprotein E genotype, and development of dementia in the neurocognitive outcomes of depression in the elderly study. 
  • Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. 
  • Low yield of thyroid-stimulating hormone testing in elderly patients with depression. 
  • Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression. 
  • Magnetic Resonance Imaging Measures of Brain Structure to Predict Antidepressant Treatment Outcome in Major Depressive Disorder. 
  • Magnetic seizure therapy improves mood in refractory major depression. 
  • Major depression and physical illness trajectories in heart failure and pulmonary disease. 
  • Major depression symptoms in primary care and psychiatric care settings: a cross-sectional analysis. 
  • Major depression, antidepressant use, and male and female fertility. 
  • Major depression, generalized anxiety disorder, and panic disorder in patients scheduled for knee arthroplasty. 
  • Major depressive disorder and comorbid cardiac disease: is there a depressive subtype with greater cardiovascular morbidity? Results from the STAR*D study. 
  • Major depressive disorder and impaired health-related quality of life among US older adults. 
  • Major depressive disorder is characterized by greater reward network activation to monetary than pleasant image rewards. 
  • Major depressive disorder treatment guidelines in America and Europe. 
  • Making clinicians lives easier: guidance on use of the QIDS self-report in place of the MADRS. 
  • Managing depression in countries with low and middle incomes: an imperative for human immunodeficiency virus/acquired immune deficiency syndrome care and treatment and general public health. 
  • Managing depression in geriatric populations. 
  • Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders. 
  • Measurement-based care in psychiatric practice: a policy framework for implementation. 
  • Medial orbital frontal lesions in late-onset depression. 
  • Medical test development and implementation: a multistep journey. 
  • Medication augmentation after the failure of SSRIs for depression. 
  • Medication preferences and adherence among individuals with severe mental illness and psychiatric advance directives. 
  • Medication-Assisted Treatment for Alcohol-Dependent Adults With Serious Mental Illness and Criminal Justice Involvement: Effects on Treatment Utilization and Outcomes. 
  • Megacity, Microscale Livable Space, and Major Depression. 
  • Mental health service use among adolescents following participation in a randomized clinical trial for depression. 
  • Metabolomic and inflammatory signatures of symptom dimensions in major depression. 
  • Metabolomic differences in heart failure patients with and without major depression. 
  • Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients. 
  • Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants. 
  • Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. 
  • Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders. 
  • Methodology and preliminary results from the neurocognitive outcomes of depression in the elderly study. 
  • Microvascular Endothelial Function and Neurocognition Among Adults With Major Depressive Disorder. 
  • Mifepristone in psychotic depression? 
  • Milnacipran: beyond a role of antidepressant. 
  • Minor depression in family practice: functional morbidity, co-morbidity, service utilization and outcomes. 
  • Modeling the onset of a depressive episode: A self-regulation perspective. 
  • Modification of Hostile Interpretation Bias in Depression: A Randomized Controlled Trial. 
  • Modification of depression by COMT val158met polymorphism in children exposed to early severe psychosocial deprivation. 
  • Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. 
  • More data on speed of remission with ECT in geriatric depression. 
  • Morphometric analysis of vascular pathology in the orbitofrontal cortex of older subjects with major depression. 
  • Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication. 
  • National dissemination of interpersonal psychotherapy for depression in veterans: therapist and patient-level outcomes. 
  • Naturalistic study of the early psychiatric use of citalopram in the United States. 
  • Negative Affectivity, Aging, and Depression: Results From the Neurobiology of Late-Life Depression (NBOLD) Study. 
  • Neighborhood structural characteristics and mental disorder: Faris and Dunham revisited. 
  • Neural indicators of emotion regulation via acceptance vs reappraisal in remitted major depressive disorder. 
  • Neural mechanisms of cognitive reappraisal in remitted major depressive disorder. 
  • NeuroBlu, an electronic health record (EHR) trusted research environment (TRE) to support mental healthcare analytics with real-world data. 
  • Neurocognitive Effects of Combined Electroconvulsive Therapy (ECT) and Venlafaxine in Geriatric Depression: Phase 1 of the PRIDE Study. 
  • Neurocognitive correlates of response to treatment in late-life depression. 
  • Neurocognitive effects of transcranial direct current stimulation (tDCS) in unipolar and bipolar depression: Findings from an international randomized controlled trial. 
  • Neurocognitive subgroups in major depressive disorder. 
  • Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis. 
  • Neuropsychological predictors of dementia in late-life major depressive disorder. 
  • Neurosteroid Levels in Patients With Bipolar Disorder and a History of Cannabis Use Disorders. 
  • Neuroticism Traits Selectively Impact Long Term Illness Course and Cognitive Decline in Late-Life Depression. 
  • Neutrophil beta(2)-adrenoceptor function in major depression: G(s) coupling, effects of imipramine and relationship to treatment outcome. 
  • New developments in electroconvulsive therapy and magnetic seizure therapy. 
  • On the Concurrent Use of Self-System Therapy and Functional Magnetic Resonance Imaging-Guided Transcranial Magnetic Stimulation as Treatment for Depression. 
  • On the psychometric validity of the domains of the PDSQ: an illustration of the bi-factor item response theory model. 
  • One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. 
  • Onset of alcohol or substance use disorders following treatment for adolescent depression. 
  • Orbitofrontal cortex volume in late life depression: influence of hyperintense lesions and genetic polymorphisms. 
  • Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial. 
  • Partial remission. A common outcome in older adults treated for major depression. 
  • Partial response as a predictor of outcome in geriatric depression. 
  • Pastoral care use among post-9/11 veterans who screen positive for mental health problems. 
  • Pathophysiology of hypercortisolism in depression. 
  • Pathophysiology of hypercortisolism in depression: pituitary and adrenal responses to low glucocorticoid feedback. 
  • Patient's therapeutic skill acquisition and response to psychotherapy, alone or in combination with medication. 
  • Patterns and correlates of major depression in Chinese adults: a cross-sectional study of 0.5 million men and women. 
  • Performance feedback deficit in geriatric depression. 
  • Persistent mild cognitive impairment in geriatric depression. 
  • Personality--life event congruence effects in late-life depression. 
  • Perspectives on depression, mild cognitive impairment, and cognitive decline. 
  • Pharmacogenetics studies in STAR*D: strengths, limitations, and results. 
  • Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication. 
  • Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure. 
  • Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. 
  • Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway. 
  • Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. 
  • Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder. 
  • Physical frailty in late-life depression is associated with deficits in speed-dependent executive functions. 
  • Physician attitudes toward treatment of depression in older medical inpatients. 
  • Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders. 
  • Plasma omega-3 polyunsaturated fatty acids and survival in patients with chronic heart failure and major depressive disorder. 
  • Platelet alpha2A-adrenoceptor function in major depression: Gi coupling, effects of imipramine and relationship to treatment outcome. 
  • Positive and negative valence systems in major depression have distinct clinical features, response to antidepressants, and relationships with immunomarkers. 
  • Possible bipolar nature of irritability in major depressive disorder. 
  • Posttraumatic stress disorder and traumatic brain Injury: Sex differences in veterans. 
  • Practitioner review: the assessment of bipolar disorder in children and adolescents. 
  • Pre-treatment attentional processing speed and antidepressant response to transcranial direct current stimulation: Results from an international randomized controlled trial. 
  • Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report. 
  • Preadult onset vs. adult onset of major depressive disorder: a replication study. 
  • Precision non-implantable neuromodulation therapies: a perspective for the depressed brain. 
  • Prediction of Acute-Phase Treatment Outcomes by Adding a Single-Item Measure of Activity Impairment to Symptom Measurement: Development and Validation of an Interactive Calculator from the STAR*D and CO-MED Trials. 
  • Prediction of nonremission to antidepressant therapy using diffusion tensor imaging. 
  • Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings. 
  • Prediction of treatment outcomes to exercise in patients with nonremitted major depressive disorder. 
  • Predictive value of family history on severity of illness: the case for depression, anxiety, alcohol dependence, and drug dependence. 
  • Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS). 
  • Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. 
  • Predictors of attrition during one year of depression treatment: a roadmap to personalized intervention. 
  • Predictors of depression outcomes in medical inpatients with chronic pulmonary disease. 
  • Predictors of depression recovery in HIV-infected individuals managed through measurement-based care in infectious disease clinics. 
  • Predictors of hopelessness among clinically depressed youth. 
  • Predictors of partial remission in older patients treated for major depression: the role of comorbid dysthymia. 
  • Predictors of recurrence in remitted late-life depression. 
  • Prefrontal mechanisms for executive control over emotional distraction are altered in major depression. 
  • Prenatal dysthymia versus major depression effects on maternal cortisol and fetal growth. 
  • Prescription pain reliever abuse and dependence among adolescents: a nationally representative study. 
  • Presenting characteristics of depressed outpatients as a function of recurrence: preliminary findings from the STAR*D clinical trial. 
  • Pretreatment brain connectivity during positive emotion upregulation predicts decreased anhedonia following behavioral activation therapy for depression. 
  • Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. 
  • Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. 
  • Prevalence and Health Characteristics of Prescription Opioid Use, Misuse, and Use Disorders Among U.S. Adolescents. 
  • Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. 
  • Prevalence and costs of major depression among elderly claimants with diabetes. 
  • Prevalence and factors associated with diagnosed depression among hospitalized cancer patients with metastatic disease. 
  • Prevalence and impact of obsessive-compulsive symptoms in depression: a STAR*D report. 
  • Prevalence and incidence of probable perinatal depression among women enrolled in Option B+ antenatal HIV care in Malawi. 
  • Prevalence and sociodemographic factors associated with depression among hospitalized patients with head and neck cancer-Results from a national study. 
  • Prevalence of incompletely penetrant Huntington's disease alleles among individuals with major depressive disorder. 
  • Prevalence of major depressive episode in CKD. 
  • Prevalence of obstructive sleep apnea in suicidal patients with major depressive disorder. 
  • Prevalence, course, and predictors of emotional distress in pregnant and parenting adolescents. 
  • Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. 
  • Probability of Major Depression Classification Based on the SCID, CIDI, and MINI Diagnostic Interviews: A Synthesis of Three Individual Participant Data Meta-Analyses. 
  • Probability of major depression diagnostic classification using semi-structured versus fully structured diagnostic interviews. 
  • Problem alcohol use and healthcare utilization among persons with cannabis use disorder in the United States. 
  • Profiles of depressive symptoms in older adults diagnosed with major depression: latent cluster analysis. 
  • Profound and reproducible patterns of reduced regional gray matter characterize major depressive disorder. 
  • Prognostic Utility of a Self-Reported Depression Questionnaire versus Clinician-Based Assessment on Renal Outcomes. 
  • Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. 
  • Psychiatric Care of the Post-September 11 Combat Veteran: A Review. 
  • Psychiatric Comorbidity of Unipolar Mood, Anxiety, and Trauma Disorders Prior to HIV Testing and the Effect on Linkage to Care Among HIV-Infected Adults in South Africa. 
  • Psychiatric comorbidity in depressed HIV-infected individuals: common and clinically consequential. 
  • Psychiatric sequelae of traumatic brain injury: a case report. 
  • Psychological distress and alcohol use disorder during the COVID-19 era among middle- and low-income U.S. adults. 
  • Psychomotor retardation in depression: biological underpinnings, measurement, and treatment. 
  • Psychosocial Predictors of Mortality Following Lung Transplantation. 
  • Psychosocial and clinical predictors of unipolar depression outcome in older adults. 
  • Psychosocial and physical correlates of chronic depression. 
  • Puberty and depression. 
  • Putamen Volume Differences Among Older Adults: Depression Status, Melancholia, and Age. 
  • Quality of life and physical activity associated to lower prevalence of depression in community-dwelling elderly subjects from Sao Paulo. 
  • Quality of life in geriatric depression: a comparison of remitters, partial responders, and nonresponders. 
  • Quantifying heterogeneity attributable to polythetic diagnostic criteria: theoretical framework and empirical application. 
  • Quantitative EEG amplitude across REM sleep periods in depression: preliminary report. 
  • Quetiapine XR: current status for the treatment of major depressive disorder. 
  • Quick recovery of orientation after magnetic seizure therapy for major depressive disorder. 
  • RCT of a psychological intervention for patients with cancer: I. mechanisms of change. 
  • Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. 
  • Randomized sham controlled trial of repetitive transcranial magnetic stimulation to the dorsolateral prefrontal cortex for the treatment of panic disorder with comorbid major depression. 
  • Randomized trial of pallidotomy versus medical therapy for Parkinson's disease. 
  • Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. 
  • Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy. 
  • Recognition of depression in medical patients with heart failure. 
  • Recovery and recurrence following treatment for adolescent major depression. 
  • Recursive subsetting to identify patients in the STAR*D: a method to enhance the accuracy of early prediction of treatment outcome and to inform personalized care. 
  • Reducing barriers to completing psychiatric advance directives. 
  • Reductions in neuronal density in elderly depressed are region specific. 
  • Relapse of depression after electroconvulsive therapy. 
  • Relationship Between Chronic Conditions and Disability in African American Men and Women. 
  • Relationship between obesity and depression: characteristics and treatment outcomes with antidepressant medication. 
  • Relationship between traumatic brain injury history and recent suicidal ideation in Iraq/Afghanistan-era veterans. 
  • Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. 
  • Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial. 
  • Relative effectiveness of reappraisal and distraction in regulating emotion in late-life depression. 
  • Reliability and Validity of the Vietnamese Depression Interview (VDI). 
  • Religion and depression in older medical inpatients. 
  • Religion and remission of depression in medical inpatients with heart failure/pulmonary disease. 
  • Religion and the presence and severity of depression in older adults. 
  • Religion, spirituality, and depression in adolescent psychiatric outpatients. 
  • Religion, spirituality, and mental health of U.S. military veterans: Results from the National Health and Resilience in Veterans Study. 
  • Religion/spirituality and depression: what can we learn from empirical studies? 
  • Religious service attendance and major depression: a case of reverse causality? 
  • Religious vs. conventional cognitive behavioral therapy for major depression in persons with chronic medical illness: a pilot randomized trial. 
  • Religiously integrated cognitive behavioral therapy: a new method of treatment for major depression in patients with chronic medical illness. 
  • Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): acute and long-term outcomes. 
  • Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). 
  • Remission of maternal depression and child symptoms among single mothers: a STAR*D-Child report. 
  • Remission of maternal depression: relations to family functioning and youth internalizing and externalizing symptoms. 
  • Remissions in maternal depression and child psychopathology: a STAR*D-child report. 
  • Remitted major depression is characterized by reduced prefrontal cortex reactivity to reward loss. 
  • Remitted major depression is characterized by reward network hyperactivation during reward anticipation and hypoactivation during reward outcomes. 
  • Repetitive Transcranial Magnetic Stimulation (rTMS) in the treatment of panic disorder (PD) with comorbid major depression. 
  • Repetitive Transcranial Magnetic Stimulation of the Supplementary Motor Area in the treatment of Tourette Syndrome: report of two cases. 
  • Reply to: Declining use of electroconvulsive therapy in U.S. general hospitals is not restricted to unipolar depression. 
  • Report by the ACNP Task Force on response and remission in major depressive disorder. 
  • Research issues in the study of difficult-to-treat depression. 
  • Research knowledge among the participants in the Treatment for Adolescents With Depression Study (TADS). 
  • Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. 
  • Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. 
  • Residual symptoms in older patients treated for major depression. 
  • Resolution of trauma-related guilt following treatment of PTSD in female rape victims: a result of cognitive processing therapy targeting comorbid depression? 
  • Resolved: psychosocial interventions can improve clinical outcomes in organic disease (pro). 
  • Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. 
  • Response inhibition predicts poor antidepressant treatment response in very old depressed patients. 
  • Response to Zhang et al. (2005): loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 45, 11-16. 
  • Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. 
  • Resting-state connectivity predictors of response to psychotherapy in major depressive disorder. 
  • Resting-state mapping of neural signatures of vulnerability to depression relapse. 
  • Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. 
  • Retention and attrition among African Americans in the STAR*D study: what causes research volunteers to stay or stray? 
  • Reward Processing in Novelty Seekers: A Transdiagnostic Psychiatric Imaging Biomarker. 
  • Risk Factors for New-Onset Depression After First-Time Traumatic Brain Injury. 
  • Role of inflammation in depression relapse. 
  • SLC6A4 variation and citalopram response. 
  • STAR*D: revising conventional wisdom. 
  • STAR*D: what have we learned? 
  • Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy. 
  • Screening for Major Depressive Disorder in Children and Adolescents: A Systematic Review for the U.S. Preventive Services Task Force. 
  • Screening for depression in cancer patients receiving radiotherapy: Feasibility and identification of effective tools in the NRG Oncology RTOG 0841 trial. 
  • Screening for major depression in private practice. 
  • Seize the Day to Implement Depression Guidelines. 
  • Seizure induction with low-amplitude-current (0.5 A) electroconvulsive therapy. 
  • Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. 
  • Selective cutoff reporting in studies of the accuracy of the Patient Health Questionnaire-9 and Edinburgh Postnatal Depression Scale: Comparison of results based on published cutoffs versus all cutoffs using individual participant data meta-analysis. 
  • Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. 
  • Self-punishment as a regulation strategy in borderline personality disorder. 
  • Self-rated global measure of the frequency, intensity, and burden of side effects. 
  • Self-regulation, rumination, and vulnerability to depression in adolescent girls. 
  • Self-reported health and physician diagnosed illnesses in women with posttraumatic stress disorder and major depressive disorder. 
  • Self-reported pain complaints among Afghanistan/Iraq era men and women veterans with comorbid posttraumatic stress disorder and major depressive disorder. 
  • Self-reported premenstrual exacerbation of depressive symptoms in patients seeking treatment for major depression. 
  • Sensitivity of cognitive tests in four cognitive domains in discriminating MDD patients from healthy controls: a meta-analysis. 
  • Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. 
  • Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine. 
  • Serotonin transporter gene moderates childhood maltreatment's effects on persistent but not single-episode depression: replications and implications for resolving inconsistent results. 
  • Serotonin transporter genotype and function in relation to antidepressant response in Koreans. 
  • Sertraline and the Cheshire cat in geriatric depression. 
  • Sertraline treatment of major depression in patients with acute MI or unstable angina. 
  • Sertraline versus imipramine to prevent relapse in chronic depression. 
  • Service use and costs of care for depressed adolescents: who uses and who pays? 
  • Sex differences in predictors of recurrent major depression among current-era military veterans. 
  • Sex differences in response to citalopram: a STAR*D report. 
  • Shared genetic etiology underlying Alzheimer's disease and major depressive disorder. 
  • Shared genetic risk between eating disorder- and substance-use-related phenotypes: Evidence from genome-wide association studies. 
  • Shifting priorities: highly conserved behavioral and brain network adaptations to chronic stress across species. 
  • Short-term dynamic psychotherapy versus pharmacotherapy for major depressive disorder: a randomized, placebo-controlled trial. 
  • Short/long heterozygotes at 5HTTLPR and white matter lesions in geriatric depression. 
  • Shortening the Edinburgh postnatal depression scale using optimal test assembly methods: Development of the EPDS-Dep-5. 
  • Simultaneous rTMS and psychotherapy in major depressive disorder: Clinical outcomes and predictors from a large naturalistic study. 
  • Sleep disturbance in psychiatric disorders: effects on function and quality of life in mood disorders, alcoholism, and schizophrenia. 
  • Sleep disturbances, circadian activity, and nocturnal light exposure characterize high risk for and current depression in adolescence. 
  • Sleep microarchitecture as a predictor of recurrence in children and adolescents with depression. 
  • Sleep polysomnography as a predictor of recurrence in children and adolescents with major depressive disorder. 
  • Slow-wave activity during non-REM sleep in men with schizophrenia and major depressive disorders. 
  • Slow-wave activity in NREM sleep: sex and age effects in depressed outpatients and healthy controls. 
  • Smoking-induced affect modulation in nonwithdrawn smokers with posttraumatic stress disorder, depression, and in those with no psychiatric disorder. 
  • Social support and locus of control as predictors of adherence to antidepressant medication in an elderly population. 
  • Social support modifies the relationship between personality and depressive symptoms in older adults. 
  • Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR(*)D trial. 
  • Somatic, positive and negative domains of the Center for Epidemiological Studies Depression (CES-D) scale: a meta-analysis of genome-wide association studies. 
  • Specific psychotherapies for childhood and adolescent depression. 
  • Speed of response to electroconvulsive therapy compared with ketamine. 
  • Spirituality and distress in sheltered battered women 
  • St John's wort and depression. 
  • Star-D: lessons learned and future implications. 
  • State of the Science of Neural Systems in Late-Life Depression: Impact on Clinical Presentation and Treatment Outcome. 
  • State-dependent responses to intracranial brain stimulation in a patient with depression. 
  • Stereoselective Steady-State Disposition and Bioequivalence of Brand and Generic Bupropion in Adults. 
  • Strengthening clinical effectiveness trials: equipoise-stratified randomization. 
  • Stressful life events, perceived stress, and 12-month course of geriatric depression: direct effects and moderation by the 5-HTTLPR and COMT Val158Met polymorphisms. 
  • Structural brain changes as biomarkers and outcome predictors in patients with late-life depression: a cross-sectional and prospective study. 
  • Structural-functional correlations between hippocampal volume and cortico-limbic emotional responses in depressed children. 
  • Study design and methodology for a multicentre, randomised controlled trial of transcranial direct current stimulation as a treatment for unipolar and bipolar depression. 
  • Subcortical lesion severity and orbitofrontal cortex volume in geriatric depression. 
  • Subcortical white matter lesions and functional impairment in geriatric depression. 
  • Substance use disorder comorbidity in major depressive disorder: a confirmatory analysis of the STAR*D cohort. 
  • Suicidal events in the Treatment for Adolescents With Depression Study (TADS). 
  • Suicide Behaviors in Bipolar Disorder: A Review and Update for the Clinician. 
  • Support for the vascular depression hypothesis in late-life depression: results of a 2-site, prospective, antidepressant treatment trial. 
  • Sustained anterior cingulate cortex activation during reward processing predicts response to psychotherapy in major depressive disorder. 
  • Symptom features of postpartum depression: are they distinct? 
  • Systematic review of multifaceted interventions to improve depression care. 
  • T-lymphocyte CREB as a potential biomarker of response to antidepressant drugs. 
  • TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics. 
  • Technology of deep brain stimulation: current status and future directions. 
  • Temporal characteristics of delta activity during NREM sleep in depressed outpatients and healthy adults: group and sex effects. 
  • Temporal dynamics of the relationship between change in depressive symptoms and cannabis use in adolescents receiving psychosocial treatment for cannabis use disorder. 
  • Test of mindfulness and hope components in a psychological intervention for women with cancer recurrence. 
  • Testing a social-cognitive model of HIV transmission risk behaviors in HIV-infected MSM with and without depression. 
  • Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). 
  • Texas Children's Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. 
  • The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. 
  • The 2-week duration criterion and severity and course of early childhood depression: implications for nosology. 
  • The Accuracy of the Patient Health Questionnaire-9 Algorithm for Screening to Detect Major Depression: An Individual Participant Data Meta-Analysis. 
  • The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation. 
  • The Concise Health Risk Tracking-Self Report: Psychometrics within a placebo-controlled antidepressant trial among depressed outpatients. 
  • The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. 
  • The Interaction of Personality and Social Support on Prospective Suicidal Ideation in Men and Women With Late-Life Depression. 
  • The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. 
  • The National Lesbian Family Study:3. Interviews with mothers of five-year-olds 
  • The Quick Inventory of Depressive Symptomatology-Self-report: a psychometric evaluation in patients with asthma and major depressive disorder. 
  • The STAR*D Project results: a comprehensive review of findings. 
  • The Treatment for Adolescents With Depression Study (TADS): demographic and clinical characteristics. 
  • The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. 
  • The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up. 
  • The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks. 
  • The Treatment of Adolescent Suicide Attempters study (TASA): predictors of suicidal events in an open treatment trial. 
  • The Use of Antidepressants in Bipolar Depression. 
  • The association between cognitive function and subsequent depression: a systematic review and meta-analysis. 
  • The association of suicide risk with negative life events and social support according to gender in Asian patients with major depressive disorder. 
  • The caregiving environments provided to children by depressed mothers with or without an antisocial history. 
  • The clinical relevance of self-reported premenstrual worsening of depressive symptoms in the management of depressed outpatients: a STAR*D report. 
  • The cost consequences of treatment-resistant depression. 
  • The critical warzone experiences (CWE) scale: initial psychometric properties and association with PTSD, anxiety, and depression. 
  • The depression treatment cascade in primary care: a public health perspective. 
  • The dysfunctional attitudes scale: psychometric properties in depressed adolescents. 
  • The effects of Brief Behavioral Activation Therapy for Depression on cognitive control in affective contexts: An fMRI investigation. 
  • The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression. 
  • The effects of posttraumatic stress disorder symptoms on educational functioning in student veterans. 
  • The effects of psychotherapy on neural responses to rewards in major depression. 
  • The effects of psychotherapy, nefazodone, and their combination on subjective assessment of disturbed sleep in chronic depression. 
  • The efficacy of acute electroconvulsive therapy in atypical depression. 
  • The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). 
  • The epidemiology of trauma and post-traumatic stress disorder in a representative cohort of young people in England and Wales. 
  • The experience of receiving a diagnosis of depression in adolescence: A pilot qualitative study in Brazil. 
  • The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations. 
  • The impact of climate change on the prevalence of mental illness symptoms. 
  • The impact of diabetes on depression treatment outcomes. 
  • The impact of race on metabolic disease risk factors in women with and without posttraumatic stress disorder. 
  • The impact of treatment-resistant depression on health care utilization and costs. 
  • The impairment of Presidents Pierce and Coolidge after traumatic bereavement. 
  • The importance of irritability as a symptom of major depressive disorder: results from the National Comorbidity Survey Replication. 
  • The influence of age on the response of major depression to electroconvulsive therapy: a C.O.R.E. Report. 
  • The influence of depressive symptoms on suicidal ideation among U.S. Vietnam-era and Afghanistan/Iraq-era veterans with posttraumatic stress disorder. 
  • The influence of lifetime depression on self-reported memory and cognitive problems: results from the National Comorbidity Survey-Replication. 
  • The influence of maternal stress and distress on disruptive behavior problems in boys. 
  • The influence of menopause status and postmenopausal use of hormone therapy on presentation of major depression in women. 
  • The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. 
  • The intricate link between violence and mental disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. 
  • The painfulness of active, but not sham, transcranial magnetic stimulation decreases rapidly over time: results from the double-blind phase of the OPT-TMS Trial. 
  • The prevalence and severity of depressive symptoms along the spectrum of unipolar depressive disorders: a post hoc analysis. 
  • The psychometric properties of the MASC in a pediatric psychiatric sample. 
  • The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study. 
  • The relationship between fibromyalgia and major depressive disorder: a comprehensive review. 
  • The relationship of MRI subcortical hyperintensities to treatment response in a trial of sertraline in geriatric depressed outpatients. 
  • The relationship of person-specific eveningness chronotype, greater seasonality, and less rhythmicity to suicidal behavior: A literature review. 
  • The role of comorbid anxiety in exercise and depression trials: Secondary analysis of the SMILE-II randomized clinical trial. 
  • The role of readiness to change in response to treatment of adolescent depression. 
  • The use of placebos in unipolar major depression: the current status. 
  • The varied clinical presentations of major depressive disorder. 
  • The vascular depression subtype: evidence of internal validity. 
  • Therapeutic reactance as a predictor of outcome in the treatment of chronic depression. 
  • Three- to four-year follow-up to an open trial of nefazodone for combat-related posttraumatic stress disorder. 
  • Three-year incidence of first-onset depressive syndrome in a population sample of older adults: the Cache County study. 
  • Thyroid Autoimmune Antibodies and Major Depressive Disorder in Women. 
  • Thyroid hormones affect recovery from depression during antidepressant treatment. 
  • Tobacco Withdrawal Symptoms Before and After Nicotine Deprivation in Veteran Smokers with Posttraumatic Stress Disorder and with Major Depressive Disorder. 
  • Toward a very brief quality of life enjoyment and Satisfaction Questionnaire. 
  • Trait anger, anger expression, and suicide attempts among adolescents and young adults: a prospective study. 
  • Trajectories of Functioning Into Emerging Adulthood Following Treatment for Adolescent Depression. 
  • Trajectories of mobility and IADL function in older patients diagnosed with major depression. 
  • Trajectories of preschool disorders to full DSM depression at school age and early adolescence: continuity of preschool depression. 
  • Transcranial magnetic stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial. 
  • Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. 
  • Transcriptome-based polygenic score links depression-related corticolimbic gene expression changes to sex-specific brain morphology and depression risk. 
  • Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. 
  • Trauma-focused cognitive-behavioral therapy for posttraumatic stress disorder in three-through six year-old children: a randomized clinical trial. 
  • Treating insomnia in depression: Insomnia related factors predict long-term depression trajectories. 
  • Treatment course with antidepressant therapy in late-life depression. 
  • Treatment for Adolescents With Depression Study (TADS): rationale, design, and methods. 
  • Treatment for Adolescents with Depression Study (TADS): safety results. 
  • Treatment of insomnia in depressed insomniacs: effects on health-related quality of life, objective and self-reported sleep, and depression. 
  • Treatment of older adults with co-morbid personality disorder and depression: a dialectical behavior therapy approach. 
  • Treatment of posttraumatic stress disorder reduces suicidal ideation. 
  • Treatment of recurrent mental depression with imipramine. 
  • Treatment outcomes for older depressed patients with earlier versus late onset of first depressive episode: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report. 
  • Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder in the Treatment for Adolescents with Depression Study. 
  • Trends and correlates of cocaine use and cocaine use disorder in the United States from 2011 to 2015. 
  • Two Studies of Connectedness to Parents and Suicidal Thoughts and Behavior in Children and Adolescents. 
  • Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. 
  • Ultradian rhythms and temporal coherence in sleep EEG in depressed children and adolescents. 
  • Unipolar depression does not moderate responses to the Sweet Taste Test. 
  • Update on magnetic seizure therapy: a novel form of convulsive therapy. 
  • Use of bupropion in combination with serotonin reuptake inhibitors. 
  • Use of the SF-36v2 Health Survey as a Screen for Risk of Major Depressive Disorder in a US Population-based Sample and Subgroup With Chronic Pain. 
  • VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. 
  • Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. 
  • Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. 
  • Vagus nerve stimulation. A potential therapy for resistant depression? 
  • Vagus nerve stimulation: a new tool for brain research and therapy. 
  • Validation of a treatment algorithm for major depression in an older Brazilian sample. 
  • Validation of depression screening scales in patients with CKD. 
  • Validity of an interviewer-administered patient health questionnaire-9 to screen for depression in HIV-infected patients in Cameroon. 
  • Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. 
  • Vascular nutritional correlates of late-life depression. 
  • Ventral striatum reactivity to reward and recent life stress interact to predict positive affect. 
  • Visual contrast sensitivity in major depressive disorder. 
  • Vmat2 heterozygous mutant mice display a depressive-like phenotype. 
  • Voice response system to measure healthcare costs: a STAR*D report. 
  • What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression? 
  • What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. 
  • What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. 
  • What is the overlap between subjective and objective cognitive impairments in MDD? 
  • What predicts attrition in second step medication treatments for depression?: a STAR*D Report. 
  • What to Expect When Switching to a Second Antidepressant Medication Following an Ineffective Initial SSRI: A Report From the Randomized Clinical STAR*D Study. 
  • When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips. 
  • White matter and subcortical gray matter lesion volume changes and late-life depression outcome: a 4-year magnetic resonance imaging study. 
  • White matter hyperintensity progression and late-life depression outcomes. 
  • White matter lesion volumes and caudate volumes in late-life depression. 
  • Why do trauma survivors become depressed? Testing the behavioral model of depression in a nationally representative sample. 
  • Work stress precipitates depression and anxiety in young, working women and men. 
  • Worsening Anxiety, Irritability, Insomnia, or Panic Predicts Poorer Antidepressant Treatment Outcomes: Clinical Utility and Validation of the Concise Associated Symptom Tracking (CAST) Scale. 
  • fMRI of alterations in reward selection, anticipation, and feedback in major depressive disorder. 
  • miR-149 and miR-29c as candidates for bipolar disorder biomarkers. 
• 

  Keywords of People

  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology
  • Olsen, Maren Karine, Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Wu, Li-Tzy, Professor in Psychiatry and Behavioral Sciences, Medicine, General Internal Medicine